Evidence map›Paper›PMID 29779163›Full record

ArticleInvestigational new drugs2019

Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology - phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells.

Mateusz Psurski, Agnieszka Łupicka-Słowik, Agnieszka Adamczyk-Woźniak, Joanna Wietrzyk, Andrzej Sporzyński

Open access · hybridAbstract read
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Recent Development of Boron-Containing Small-Molecule Anticancer Agents.ACS pharmacology & translational science · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Nanotheranostics · 2023
    Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mateusz PsurskiHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla St, 53114, Wrocław, Poland. mateusz.psurski@iitd.pan.wroc.pl.ORCID 0000-0001-8866-7149
Agnieszka Łupicka-SłowikDepartment of Medicinal Chemistry and Microbiology, Wrocław University of Science and Technology, 29 Wybrzeże Wyspiańskiego St, 50370, Wrocław, Poland.
Agnieszka Adamczyk-WoźniakFaculty of Chemistry, Warsaw University of Technology, 3 Noakowskiego St, 00664, Warsaw, Poland.
Joanna WietrzykHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla St, 53114, Wrocław, Poland.
Andrzej SporzyńskiFaculty of Chemistry, Warsaw University of Technology, 3 Noakowskiego St, 00664, Warsaw, Poland.
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy · PLWarsaw University of Technology · PLWrocław University of Science and Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective The aim of the study was to evaluate the antiproliferative potential of simple phenylboronic acid and benzoxaborole derivatives as well as to provide preliminary insight into their mode of action in cancer cells in vitro. Methods The antiproliferative activity was assessed in five diverse cancer cell lines via the SRB method (sulforhodamine B) or MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method after 72 h of treatment. Further studies of the mechanism of action consisted of the influence of the compounds on cell cycle progression and apoptosis induction, which was assessed by flow cytometry, caspase-3 enzymatic activity, fluorescence microscopy and western blot analysis. Results A clear structure-activity relationship was observed for both groups of compounds with several representatives evaluated as highly active antiproliferative agents with low micromolar [Formula: see text] values. 2-Fluoro-6-formylphenylboronic acid (18) and 3-morpholino-5-fluorobenzoxaborole (27) exhibited strong cell cycle arrest induction in G

Indexed as

Drug DiscoveryAntineoplastic AgentsApoptosisBoronic AcidsCell Cycle CheckpointsCell ProliferationFemaleHumansMorpholinesOvarian NeoplasmsTumor Cells, CulturedAntineoplastic Agentsbenzeneboronic acidBoronic AcidsMorpholinesAnticancerApoptosisBenzoxaboroleOvarian cancerPhase cycle arrestPhenylboronic acid

Identifiers

PMID29779163
PMCPMC6510839
OpenAlexW2804723046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.